Literature DB >> 7630480

Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in Dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats.

S L Shepheard1, D J Williamson, J Williams, R G Hill, R J Hargreaves.   

Abstract

Dural plasma extravasation produced by electrical stimulation of the trigeminal ganglion was measured in rats and the concomitant expression of c-fos mRNA produced in the trigeminal nucleus caudalis (NtV) was measured using in situ hybridization techniques. The non-peptide NK1 receptor selective antagonist CP-99,994 (1-3000 micrograms kg-1) and the 5HT1D receptor agonist sumatriptan (1-1000 micrograms kg-1) reduced dural plasma extravasation dose-dependently with ID50S of 52 micrograms kg-1 and 30 micrograms kg-1 respectively. CP-99,994 (1000 micrograms kg-1). a compound known to have good brain penetration, decreased c-fos mRNA expression in the NtV by 37 +/- 7% without disruption of the blood brain barrier (BBB). Sumatriptan (1000 micrograms kg-1), known to be poorly brain penetrant, had no significant effect on c-fos mRNA expression in the NtV unless the BBB was disrupted by infusion of a hyperosmolar mannitol solution after which sumatriptan decreased c-fos mRNA expression by 65 +/- 11%. The results suggest that brain penetrant NK1 receptor antagonists may have anti-migraine effects peripherally through blockade of dural extravasation and centrally by inhibition of nociceptive pathways. Furthermore the data indicates that the anti-migraine action of sumatriptan must be predominantly peripherally mediated, be it via inhibition of plasma extravasation or direct vasoconstriction, since it had little effect on the activation of neurones in the NtV unless the BBB was disrupted.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7630480     DOI: 10.1016/0028-3908(94)00153-j

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  23 in total

Review 1.  Where do triptans act in the treatment of migraine?

Authors:  Andrew H Ahn; Allan I Basbaum
Journal:  Pain       Date:  2005-05       Impact factor: 6.961

Review 2.  Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.

Authors:  P Tfelt-Hansen; P De Vries; P R Saxena
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

3.  Tissue injury regulates serotonin 1D receptor expression: implications for the control of migraine and inflammatory pain.

Authors:  Andrew H Ahn; Allan I Basbaum
Journal:  J Neurosci       Date:  2006-08-09       Impact factor: 6.167

Review 4.  5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?

Authors:  Lars Neeb; Jannis Meents; Uwe Reuter
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

5.  Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist.

Authors:  M J Cumberbatch; D J Williamson; G S Mason; R G Hill; R J Hargreaves
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

Review 6.  Modelling headache and migraine and its pharmacological manipulation.

Authors:  S E Erdener; T Dalkara
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

7.  Melatonin treatment decreases c-fos expression in a headache model induced by capsaicin.

Authors:  Fabiano C Tanuri; Eliângela de Lima; Mario F P Peres; Francisco R Cabral; Maria da Graça Naffah-Mazzacoratti; Esper Abrão Cavalheiro; José Cipolla-Neto; Eliova Zukerman; Débora Amado
Journal:  J Headache Pain       Date:  2009-01-27       Impact factor: 7.277

Review 8.  Does sumatriptan cross the blood-brain barrier in animals and man?

Authors:  Peer Carsten Tfelt-Hansen
Journal:  J Headache Pain       Date:  2009-12-10       Impact factor: 7.277

Review 9.  Animal migraine models for drug development: status and future perspectives.

Authors:  Inger Jansen-Olesen; Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

Review 10.  Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.

Authors:  Carlos M Villalón; David Centurión
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-17       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.